Showing 5041-5050 of 5771 results for "".
- Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-completes-enrolment-of-phase-1-clinical-trial-evaluating-thr-687-for-the-treatment-of-dme/2476849/Oxurion NV announced the completion of enrollment of patients in a phase 1 trial with THR-687. The open-label, multicenter, dose escalation phase 1 study is evaluating the safety of a single intravitreal injection of escalating dose levels (3) of THR-687 for the treatment of patients with diabeti
- Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at EURETINAhttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-euretina/2476845/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (dry AMD) will be presented during the European Society of Retina Specialists (EURETINA) Congress that is being
- Alimera Sciences Launches Iluvien in Germany For Noninfectious Uveitishttps://modernod.com/news/alimera-sciences-launches-iluvien-in-germany-for-noninfectious-uveitis/2476846/Alimera Sciences announced that it will immediately commence the launch of Iluvien in Germany for the prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIPU). Following the European Union’s Mutual Recognition Procedure in March 2019, Germany is t
- Horus Pharma Launches Neovis Total Multi for Dry Eye in New Sizehttps://modernod.com/news/horus-pharma-launches-neovis-total-multi-for-dry-eye-in-new-size/2476843/Horus Pharma announced the launch of a new 15ml bottle of Neovis Total Multi for the French, Belgian, and Spanish markets. The product is prescribed as third-line therapy for the treatment of dry eyes with keratitis or dry keratoconjunctivitis, following unsuccessful treatment with low-viscosity
- Oxurion to Make a Late-Breaker Presentation of Topline THR-149 Phase 1 Clinical Data at EURETINAhttps://modernod.com/news/oxurion-to-make-a-late-breaker-presentation-of-topline-thr-149-phase-1-clinical-data-at-euretina/2476844/Oxurion NV announced that it will make a late breaking presentation covering the data from its positive phase 1 clinical study with THR-149, a potent plasma kallikrein inhibitor, in patients with diabetic macular edema (DME) at the 19th European Society of Retina Specialists (EURETINA) 2019 Congr
- Lenstec Completes FDA Trial for SBL-3 IOLhttps://modernod.com/news/lenstec-completes-fda-trial-for-sbl-3-iol/2476837/Lenstec announced that it has completed its FDA trial for the SBL-3 IOL (Segmented Bifocal Lens), an asymmetric multifocal refractive IOL designed to provide patients with superior near, intermediate, and distance vision. It also offers improved contrast sensitivity and minimizes halos and glare
- Hoya Vision Care Plans $25 Million Dollar Expansion of U.S. Labhttps://modernod.com/news/hoya-vision-care-plans-25-million-dollar-expansion-of-u-s-lab/2476833/Hoya Vision Care announced plans to invest more than $25 million in its Ramsey, Minnesota facility, according to a report in VisionMonday. The investment in facility
- RightEye: New Research Demonstrates Reliability of Eye Tracking Data to Identify and Measure Severity of Traumatic Brain Injurieshttps://modernod.com/news/righteye-new-research-demonstrates-reliability-of-eye-tracking-data-to-identify-and-measure-severity-of-traumatic-brain-injuries/2476832/RightEye announced the results of a recent study published in the peer-reviewed journal Concussion that shows how RightEye’s FDA-cleared technology accurately measures deficits in certain eye movements that r
- AmblyoPlay Now Offers its Vision Therapy Solution for Lazy Eye in the United Stateshttps://modernod.com/news/amblyoplay-now-offers-its-vision-therapy-solution-for-lazy-eye-in-the-united-states/2476828/AmblyoPlay, a home-based vision therapy solution for children and adults with amblyopia (lazy eye), mild strabismus (crossed or turned eye) or convergence insufficiency (eyes unable to focus together), announced the launch of its software-based vision therapy solution in the U.S. market. I
- Topcon Launches the Maestro2 with Automated OCTAhttps://modernod.com/news/topcon-launches-the-maestro2-with-automated-octa/2476826/Topcon has announced the launch of the Maestro2 Automated OCT/Fundus Camera, now with OCTA. Building on the success of its predecessor, the 3D OCT-1 Maestro, the new Maestro2 adds even more clinical utility to its multimodality platform, according to a company news release. The Maestro2 is